{
    "nctId": "NCT05257395",
    "briefTitle": "A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer",
    "officialTitle": "A Phase III Study to Evaluate the Efficacy and Safety of XZP-3287 Combined With Letrozole/Anastrozole Versus Placebo Combined With Letrozole/Anastrozole in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 372,
    "primaryOutcomeMeasure": "Investigator-assessed progression free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients aged \u226518 years and \u226475 years old;\n2. Patient is in the menopausal state\uff1b\n3. Histologically or cytologically confirmed locally advanced, recurrent or metastatic breast cancer, which was pathologically confirmed to be HR-positive and HER2-negative;\n4. Evidence of locally advanced, recurrent, or metastatic disease that is not amenable to curative surgical resection or radiation therapy and is not clinically amenable to chemotherapy;\n5. No prior systemic anticancer therapy for locally advanced, recurrent, or metastatic disease;\n6. At least one measurable lesion (based on RECIST v1.1) or only bone metastases;\n7. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;\n8. Adequate organ and marrow function;\n9. Patient of childbearing age must undergo a serum pregnancy test within 7 days before randomization, and the result is negative; patient is willing to use a medically approved high-efficiency contraceptive method during the study period and within 6 months after the last study drug treatment;\n10. Patient with acute toxic reactions caused by previous anti-tumor treatments or surgical operations were alleviated to grade 0 to 1 (NCI-CTCAE v5.0), or to the level specified by the enrollment criteria;\n11. Patient has signed informed consent before any trial related activities.\n\nExclusion Criteria:\n\n1. Patients with disease recurrence or metastasis at or within 12 months after previous neoadjuvant or adjuvant therapy with endocrine drugs;\n2. Patient with visceral crisis or brain metastases, except for patient with stable brain metastases;\n3. Patient had clinically significant pleural effusions, ascites effusions, or pericardial effusions in the 4 weeks before enrollment;\n4. Patient who received prior treatment with mTOR inhibitors or CDK4/6 inhibitors ;\n5. Participation in a prior treatment of major surgery, chemotherapy, radiotherapy, and any anti-tumor treatment within 14 days before enrollment\uff1b\n6. Patient who participated in other clinical trials within 14 days before enrollment or within 5 half-lives of the trial drug, whichever is longer;\n7. Patient used CYP3A4 potent inhibitors or potent inducers within 14 days before enrollment or within 5 half-lives of the drug, whichever is longer;\n8. Initiation of bisphosphonates or RANKL inhibitors within 7 days before enrollment, and subjects who have initiated treatment \\> 7 days before enrollment should not change the method of use;\n9. Any other malignant tumor has been diagnosed within 5 years before randomization;\n10. Patient is in the active stage of HBV, HCV or co-infected with HBV, HCV, or Patient with positive HIV antibody;\n11. Patient with severe infection within 4 weeks before enrollment, or unexplained fever\\> 38.3\u2103 during screening/before enrollment;\n12. Patient with heart function impaired or clinically significant heart disease within 6 months before enrollment;\n13. Cerebrovascular accident occurred within 6 months before enrollment, including history of transient ischemic attack or stroke; pulmonary embolism;\n14. Inability to swallow, intestinal obstruction or other factors that affect the taking and absorption of the drug;\n15. Patient with a known hypersensitivity to any of the excipients in this study;\n16. A prior history of autologous or allogeneic hematopoietic stem cell transplantation;\n17. A prior history of psychotropic drug abuse or drug use;\n18. Nursing Mothers;\n19. The researchers considered that there were some cases that were not suitable for inclusion.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}